A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia
- 31 March 2004
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 14 (2) , 87-92
- https://doi.org/10.1016/s0924-977x(03)00109-3
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Managing Schizophrenia during the Stable Phase: Is There Consensus among Practice Guidelines?The Canadian Journal of Psychiatry, 2002
- A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with SchizophreniaNew England Journal of Medicine, 2002
- Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?American Journal of Psychiatry, 2002
- Systematic meta-review of depot antipsychotic drugs for people with schizophreniaThe British Journal of Psychiatry, 2001
- Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysisEuropean Psychiatry, 2001
- Risperidone versus haloperidol: II. Cost-effectivenessClinical Therapeutics, 1998
- Predictors of Relapse and Rehospitalization in Schizophrenia and Schizoaffective DisorderSchizophrenia Bulletin, 1998
- Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study*Journal of Clinical Psychopharmacology, 1995
- Depot Antipsychotic DrugsDrugs, 1994
- Factors related to tardive dyskinesiaAmerican Journal of Psychiatry, 1979